vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and International General Insurance Holdings Ltd. (IGIC). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $403.8M, roughly 1.5× International General Insurance Holdings Ltd.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 26.0%, a 14.8% gap on every dollar of revenue.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
China Taiping Insurance Holdings Company Limited (CTIH) formerly China Insurance International Holdings Company Limited (CIIH), is a Chinese insurance conglomerate. The company has strong Chinese Central Government background despite being incorporated in Hong Kong. It is considered as a red chip company.
EXEL vs IGIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $403.8M |
| Net Profit | $244.5M | $105.1M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | — |
| Net Margin | 40.8% | 26.0% |
| Revenue YoY | 5.6% | — |
| Net Profit YoY | 74.8% | — |
| EPS (diluted) | $0.89 | $2.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | — | ||
| Q3 25 | $568.3M | $403.8M | ||
| Q2 25 | $555.4M | $261.9M | ||
| Q1 25 | $566.8M | — | ||
| Q3 24 | $539.5M | $369.6M | ||
| Q2 24 | $637.2M | $265.8M | ||
| Q1 24 | $425.2M | — |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | — | ||
| Q3 25 | $184.8M | $105.1M | ||
| Q2 25 | $159.6M | $61.4M | ||
| Q1 25 | $139.9M | — | ||
| Q3 24 | $118.0M | $-134.4M | ||
| Q2 24 | $226.1M | $70.7M | ||
| Q1 24 | $37.3M | — |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — | ||
| Q1 24 | 95.0% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | — | ||
| Q2 25 | 33.6% | 24.2% | ||
| Q1 25 | 28.8% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 43.3% | -73.3% | ||
| Q1 24 | 6.9% | — |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | — | ||
| Q3 25 | 32.5% | 26.0% | ||
| Q2 25 | 28.7% | 23.5% | ||
| Q1 25 | 24.7% | — | ||
| Q3 24 | 21.9% | -36.4% | ||
| Q2 24 | 35.5% | 26.6% | ||
| Q1 24 | 8.8% | — |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | $2.31 | ||
| Q2 25 | $0.55 | $1.36 | ||
| Q1 25 | $0.47 | — | ||
| Q3 24 | $0.40 | $1.82 | ||
| Q2 24 | $0.77 | $1.55 | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $244.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $654.8M |
| Total Assets | $2.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | $244.7M | ||
| Q2 25 | $1.0B | $164.8M | ||
| Q1 25 | $1.1B | — | ||
| Q3 24 | $1.2B | $219.2M | ||
| Q2 24 | $1.0B | $237.3M | ||
| Q1 24 | $963.3M | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | $654.8M | ||
| Q2 25 | $2.1B | $662.3M | ||
| Q1 25 | $2.2B | — | ||
| Q3 24 | $2.3B | $540.5M | ||
| Q2 24 | $2.1B | $588.2M | ||
| Q1 24 | $2.1B | — |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.8B | $2.1B | ||
| Q1 25 | $2.9B | — | ||
| Q3 24 | $3.0B | $1.8B | ||
| Q2 24 | $2.8B | $2.0B | ||
| Q1 24 | $2.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | — | ||
| Q3 25 | $49.0M | — | ||
| Q2 25 | $211.4M | $27.2M | ||
| Q1 25 | $240.3M | — | ||
| Q3 24 | $271.3M | — | ||
| Q2 24 | $119.5M | $120.7M | ||
| Q1 24 | $68.8M | — |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | $26.8M | ||
| Q1 25 | $236.3M | — | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | $119.8M | ||
| Q1 24 | $59.1M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | 10.2% | ||
| Q1 25 | 41.7% | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | 45.1% | ||
| Q1 24 | 13.9% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | 0.2% | ||
| Q1 25 | 0.7% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | 0.3% | ||
| Q1 24 | 2.3% | — |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | 0.44× | ||
| Q1 25 | 1.72× | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | 1.71× | ||
| Q1 24 | 1.84× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
IGIC
Segment breakdown not available.
